Emerging GLP-1 Delivery Methods:
What's in the Pipeline Right Now
GLP-1 innovation is accelerating. Monthly injections, needle-free patches, triple agonists, and more are in clinical trials. Here's what's coming and when.
The GLP-1 space exploded in 2025. In a single year, this drug class accounted for 16.4% of all historical GLP-1 clinical trials. But the innovation isn't just about new drugs — it's about new ways to deliver them.
We've gone from weekly injections to daily pills. Now researchers are working on monthly shots, patch delivery systems, and even more powerful molecules that hit multiple targets at once. Some of these options are only months away from approval. Others are years off. This guide separates the hype from the reality.
Monthly & Ultra-Long-Acting Injections
The most immediately available emerging option is less frequent dosing. Instead of injecting once a week, what if you only had to inject once a month?
Pfizer's PF-08653944 (MET-097i)
Pfizer is testing a once-monthly GLP-1 agonist designed for weight loss. In Phase 2b trials (VESPER-3), the highest dose achieved 12.3% placebo-adjusted weight loss at week 28 with monthly maintenance dosing. To put that in perspective: Ozempic and Wegovy typically deliver 10-15% weight loss over a longer period.
What's next: 10 Phase 3 trials are expected to launch in 2026. If they succeed, approval could come by 2027-2028.
The advantage here is obvious: inject once a month instead of once a week. That's four fewer injections per month, which could improve adherence and simplify the routine for many people.
Novo Nordisk's MariTide
Novo Nordisk (the maker of Ozempic and Wegovy) is developing MariTide, a long-acting GLP-1 receptor agonist combined with a GIP receptor antagonist. In Phase 2 trials, it showed efficacy with both monthly dosing and every-8-week dosing options.
Status: Still in clinical development. Phase 3 data will drive the timeline for regulatory submission.
MariTide is a dual agonist (two receptors), not triple like retatrutide, but the ultra-long-acting formulation could be a game-changer for people who struggle with weekly injection schedules or want fewer clinic visits.
Retatrutide: The Triple Agonist
While most current GLP-1 drugs target a single receptor, Eli Lilly's retatrutide breaks the mold. It's a novel triple agonist that activates three receptors at once: GLP-1, GIP, and glucagon. This is a fundamentally different approach to weight loss and metabolic health.
The Science: Three Receptors, One Drug
GLP-1 receptors suppress appetite and slow gastric emptying. GIP receptors enhance insulin secretion and influence weight regulation. Glucagon receptors drive energy expenditure and fat metabolism. By activating all three, retatrutide works on multiple metabolic pathways simultaneously.
Phase 3 Results: Unprecedented Weight Loss
The TRIUMPH-4 Phase 3 trial tested retatrutide in people with obesity. The results were striking:
| Dose | Placebo-Adjusted Weight Loss | Context |
|---|---|---|
| 12 mg (highest) | 28.7% | Unprecedented in Phase 3 |
| 9 mg | 26.4% | Still exceeds most GLP-1 results |
| Placebo | — | Baseline comparison |
To contextualize: Wegovy achieves roughly 15-22% weight loss depending on adherence and individual factors. The 28.7% figure represents a significant leap forward.
Additional Benefits: Osteoarthritis Pain Reduction
Retatrutide also showed an unexpected secondary benefit in TRIUMPH-4: patients with knee osteoarthritis experienced pain reduction. This opens up a potential dual-benefit pathway — weight loss plus improved joint pain — which is important because obesity and osteoarthritis often coexist.
Delivery & Timeline
Like other GLP-1 drugs, retatrutide is administered as a once-weekly subcutaneous injection. It still uses a needle, so it's not a needle-free innovation, but the efficacy gains are substantial.
Not approved yet. Retatrutide is NOT FDA-approved. Eli Lilly is running seven Phase 3 trials with readouts expected in 2026. If successful, the company could seek FDA approval by late 2026 or 2027. Expected availability: 2027-2028.
The drug will likely be branded as a successor to Mounjaro (tirzepatide), but under a different name once approved for weight loss.
Patch Delivery: Microneedle & Transdermal
The dream delivery method for many patients is a patch: stick it on your skin, and forget it for a week or a month. No needles, no inhalers, no pills to remember. Research teams are actively pursuing this goal, but the biochemistry is challenging.
Microneedle Patches (Most Promising)
Microneedle patches use microscopic needles — so small they're painless — to penetrate the outer layer of skin and deliver medication into the dermis below. Unlike traditional hypodermic needles, patients don't feel them. The needles dissolve or are absorbed after delivery.
Current status: Early clinical trials. Research teams have demonstrated that bioavailability (the amount of drug that reaches the bloodstream) is comparable to subcutaneous injection in preclinically relevant models.
Timeline: If Phase 1 and Phase 2 trials progress on schedule, microneedle patches could be available for GLP-1 delivery within 3-5 years. Most optimistic estimates: 2028-2030.
The advantage: painless, truly needle-free from the patient's perspective, and potentially suitable for longer-acting formulations (weekly or monthly patches).
Transdermal Patches (No Needles at All)
A true transdermal patch — drug absorbed directly through the skin with no needles whatsoever — would be the gold standard. Researchers have shown that transdermal semaglutide can decrease body weight, blood glucose, and triglycerides in mice. But human trials haven't started yet.
Not in human trials. Transdermal patches for GLP-1 are still in preclinical/animal research. No human clinical data exists.
The challenge: GLP-1 agonists are peptide drugs — chains of amino acids. Unlike small lipophilic molecules (like fentanyl or estrogen, which work well in transdermal patches), peptides are structurally fragile. They degrade with heat, light, and enzymes. They're also hydrophilic (water-loving), not lipophilic (fat-loving), which means they don't naturally permeate skin.
Researchers are exploring chemical enhancers and novel polymer systems to overcome these barriers, but progress is slow. Realistic timeline: 5-10+ years before human trials, if they happen at all.
Other Emerging Routes of Administration
Intranasal Delivery
The nasal mucosa has a rich blood supply and high permeability, making it an attractive target for peptide delivery. Intranasal GLP-1 formulations are being explored by multiple research teams.
Status: Preclinical and early clinical research. No FDA-approved intranasal GLP-1 products yet, but the pathway is technically feasible.
Timeline: If development progresses, intranasal options could emerge by 2027-2029, potentially competing with microneedle patches and long-acting injectables.
Inhaled Formulations
Inhalable insulin exists (Afrezza), so inhalable GLP-1 is theoretically possible. However, published data on GLP-1 inhalation is limited. The lung delivers peptides effectively, but controlling dose and ensuring consistent bioavailability is complex.
Status: Very early research. Not advanced enough for clinical trials yet.
Implantable Depots
Researchers are exploring implantable devices or pellets that release GLP-1 slowly over months. Imagine a subcutaneous implant the size of a grain of rice that provides steady drug release for 3-6 months without injections.
Status: Preclinical. No human trials have begun.
Challenge: Regulatory pathway is uncertain, and the implant procedure (minor surgery) might deter patients who want to avoid needles but can tolerate injections.
Timeline & Status: What's Coming When?
Here's a realistic roadmap of emerging methods and their expected availability:
| Method | Current Status | Expected Availability | Estimated Timeline |
|---|---|---|---|
| Pfizer PF-08653944 (monthly injection) | Phase 2b complete 10 Phase 3 trials starting 2026 | FDA approval likely | 2027-2028 |
| Retatrutide (triple agonist) | Phase 3 ongoing 7 trials with 2026 readouts | FDA approval likely | 2027-2028 |
| MariTide (monthly/every-8-week) | Phase 2 complete | Phase 3 in progress | 2028-2029 |
| Microneedle patches | Early clinical trials | Conditional approval possible | 2028-2030 |
| Intranasal formulations | Preclinical / early research | Clinical trials may start | 2027-2029 |
| Transdermal patches | Preclinical (animal studies) | Very uncertain | 5-10+ years |
| Implantable depots | Preclinical | Very uncertain | 5-10+ years |
Note: Timelines are based on typical FDA approval pathways (Phase 3 typically 2-3 years). Actual approval dates depend on trial results, regulatory interactions, and manufacturing scale-up. These estimates should be treated as informed guesses, not guarantees.
What This Means for Patients Right Now
If you're considering GLP-1 treatment today, the emerging options shouldn't change your decision. Here's why:
Today's Options Are Proven
Oral pills (Wegovy, Foundayo), auto-injector pens (Ozempic, Mounjaro), and compounded formulations are available now and have years of safety and efficacy data. They work. If you're eligible and interested, there's no reason to wait for something that might be available in 2027 or 2028.
The Direction Is Clear
The trends are unmistakable: less frequent dosing, fewer needles, and more powerful molecules. Within 2-3 years, once-monthly injections will likely be available. Within 5 years, needle-free patches might be an option. This is the direction the entire industry is moving.
If You're Needle-Averse
Oral pills (Wegovy, Foundayo) are available right now and offer genuine needle-free treatment. You don't need to wait for a patch. Talk to your provider about oral options that fit your medical situation.
If You Want Maximum Efficacy
Retatrutide (coming 2027-2028) will likely offer superior weight loss compared to current GLP-1 drugs. If efficacy is your main priority and you can wait 18-24 months, keeping tabs on retatrutide's Phase 3 trials makes sense.
If You're on Weekly Injections
Monthly injection options (Pfizer's PF-08653944, MariTide) could significantly simplify your routine. If fewer injections would improve your adherence or quality of life, it's worth waiting for 2027-2028 approval timelines.
Frequently Asked Questions
Is retatrutide available now?
No. Retatrutide is in Phase 3 clinical trials. Seven trials with readouts expected in 2026. If results are positive, Eli Lilly will seek FDA approval, with likely approval by late 2026 or 2027. Expected commercial availability: 2027-2028.
Will retatrutide be more expensive than current GLP-1 drugs?
Unknown. Eli Lilly's tirzepatide (Mounjaro/Zepbound) is priced comparably to semaglutide-based drugs. Retatrutide might follow a similar pricing strategy, or it might command a premium due to superior efficacy. Insurance coverage will likely depend on medical need and trial-and-error with other GLP-1 drugs first (step therapy).
Can I switch from weekly Ozempic to monthly PF-08653944 once it's approved?
Likely yes, but you'd need to talk to your prescriber. Both are GLP-1 agonists, so the transition should be straightforward. However, dosing schedules and potency differ, so your provider will need to adjust your regimen appropriately.
How much weight loss will retatrutide achieve?
In Phase 3, the highest dose (12 mg) achieved 28.7% placebo-adjusted weight loss. Lower doses achieved 26.4-24% weight loss. For context, an average person losing 25% of their body weight would lose roughly 50-75 lbs, depending on starting weight. Real-world results may vary.
What about side effects from retatrutide? Is it safe?
All Phase 3 trial data for retatrutide has not yet been published in peer-reviewed journals, so the full safety profile is not public. Like other GLP-1 drugs, nausea and gastrointestinal effects are expected. More data will be available as Phase 3 results are released in 2026.
Will transdermal GLP-1 patches ever work?
It's theoretically possible, but practically very difficult. GLP-1 peptides degrade with heat, light, and enzymes. Standard transdermal patches don't work for large hydrophilic molecules. Researchers would need to develop novel chemical enhancers or encapsulation technologies. Even then, a realistic timeline is 5-10+ years, if it happens at all.
Should I wait for emerging options, or start treatment now?
Start now if you're eligible and motivated. Weight loss treatments are most effective when started early and sustained long-term. Waiting 2-3 years for a new option risks prolonging your symptoms and comorbidities. Current approved options are proven, safe, and effective. Emerging options will be available in a few years if you want to switch later.
What's the difference between a GLP-1 and a GLP-1/GIP combo?
A GLP-1 drug (like semaglutide) targets one receptor. A GLP-1/GIP combo (like tirzepatide in Mounjaro) targets two receptors. Retatrutide targets three (GLP-1 + GIP + glucagon). More receptors = more metabolic pathways activated = potentially greater efficacy, but also more side effects. The tradeoff is managed through dose titration.
Are microneedle patches really painless?
Yes. Microneedles are so small (typically 200-500 micrometers) that they don't reach the pain-sensing nerve endings in the dermis. Early studies report little to no pain. The patches are also designed to be applied without any training or technique — just like a normal adhesive patch.
Want to Explore Your Options Today?
While emerging methods are on the horizon, approved GLP-1 treatments are available right now. Explore your current delivery options:
Sources
- Eli Lilly. "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs" (December 2025). TRIUMPH-4 Phase 3 results. investor.lilly.com
- Pfizer. "Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust Weight Loss" (VESPER-3 Phase 2b). pfizer.com
- Clinical Trials Arena. "2025 GLP-1 Trial Activity." clinicaltrialsarena.com
- Drug Development & Delivery. "Innovative Drug Delivery Approaches for GLP-1 Agonists." drug-dev.com
- PMC/NIH. "Transdermal semaglutide in mice." pmc.ncbi.nlm.nih.gov
Stay Informed
Get the GLP-1 Insider Brief
Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.
No spam. Unsubscribe any time.